BioSpace News Archive

Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler’ covid-19 recovery patients in Europe

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and year ended Dec. 31, 2020 financial results following the close of U.S. financial markets on March 1.

Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Courtney Barton has joined the company as Chief Compliance Officer and Chief of Staff.

further advancing the science of urology, improving health care quality and ultimately improving the lives of the millions of people affected by prostate cancer, bladder cancer and other urologic disease.

Central Logic, the leading healthcare access and orchestration company, announced today that NEJM Catalyst, a renowned healthcare journal, has published a case study on the origin and successful outcomes of the Arizona Surge Line.

Blackfynn, a company using a systematic approach that combines data, technology and disease-specific clinical expertise to develop a growing pipeline of targeted, clinical-stage therapeutics for Parkinson’s and neurodegeneration, today announced that it has entered into an agreement with an undisclosed partner to acquire rights to a Phase 3-ready drug to treat Parkinson’s.

Metabolon, Inc. has entered into to a multi-year collaborative agreement with Cleveland Clinic to provide Metabolon’s Precision Metabolomics™ services in support of drug development and related research efforts.

WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) (“WPD”) and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system,

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, announced the appointment of Laura Kelly as Director of Clinical Operations.

ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced the appointment of Neil Graham, MBBS, MD, MPH as an independent director.